MiRus

Boston Scientific acquired a 34% equity stake in MiRus for $1.5 billion, with an option to acquire the rest of its TAVR business for up to $3 billion in additional payments.

Boston Scientific invested $1.5 billion for an approximately 34% equity stake in MiRus LLC, a developer of biomaterials and implants for cardiovascular and orthopedic diseases. Boston Scientific also received an exclusive option to acquire MiRus' TAVR system.

MiRus acquired a fully operational 50,000 sqft orthopaedic and spine manufacturing plant in Marietta, GA, adding to its current 20,000 sqft facility. The expansion follows FDA clearance of its MoRe superalloy for medical implants.